Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J W Clark

Showing results (191-200 of 213) with videos related to

Pageof 22
Sort By:
Cancer Research|November 15, 1990
Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimenJ W Clark, J W Smith, R G Steis, et al.
Cancer Research|January 1, 1990
Immunomodulatory properties and toxicity of interleukin 2 in patients with cancerW J Urba, R G Steis, D L Longo, et al.
Clinical Immunology and Immunopathology|July 1, 1990
T-cell subsets in healthy teenagers: transition to the adult phenotypeD J Tollerud, S T Ildstad, L M Brown, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 10, 2001
Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignanciesD P Ryan, J G Supko, J P Eder, et al.
Blood|October 1, 1991
Prolonged, continuous treatment of hairy cell leukemia patients with recombinant interferon-alpha 2aJ W Smith, D L Longo, W J Urba, et al.
Cancer|August 1, 1985
Molecular and immunologic analysis of a chronic lymphocytic leukemia case with antibodies against human T-cell leukemia virusJ W Clark, B H Hahn, D L Mann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1990
Toxicity, immunogenicity, and tumor radioimmunodetecting ability of two human monoclonal antibodies in patients with metastatic colorectal carcinomaR G Steis, J A Carrasquillo, R McCabe, et al.
Blood|November 1, 1988
Rearrangement of both immunoglobulin and T-cell receptor genes in a prolymphocytic variant of hairy cell leukemia patient resistant to interferon-alphaS L Giardina, H A Young, C R Faltynek, et al.
British Journal of Cancer|June 30, 2005
A phase I clinical trial of continual alternating etoposide and topotecan in refractory solid tumoursR T Penson, M V Seiden, U A Matulonis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1990
Treatment of hairy cell leukemia with alternating cycles of pentostatin and recombinant leukocyte A interferon: results of a phase II studyA Martin, S Nerenstone, W J Urba, et al.
Pageof 22

Showing results (191-200 of 213) with videos related to

Sort By:
Pageof 22
Cancer Research|November 15, 1990
Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimenJ W Clark, J W Smith, R G Steis, et al.
Cancer Research|January 1, 1990
Immunomodulatory properties and toxicity of interleukin 2 in patients with cancerW J Urba, R G Steis, D L Longo, et al.
Clinical Immunology and Immunopathology|July 1, 1990
T-cell subsets in healthy teenagers: transition to the adult phenotypeD J Tollerud, S T Ildstad, L M Brown, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 10, 2001
Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignanciesD P Ryan, J G Supko, J P Eder, et al.
Blood|October 1, 1991
Prolonged, continuous treatment of hairy cell leukemia patients with recombinant interferon-alpha 2aJ W Smith, D L Longo, W J Urba, et al.
Cancer|August 1, 1985
Molecular and immunologic analysis of a chronic lymphocytic leukemia case with antibodies against human T-cell leukemia virusJ W Clark, B H Hahn, D L Mann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1990
Toxicity, immunogenicity, and tumor radioimmunodetecting ability of two human monoclonal antibodies in patients with metastatic colorectal carcinomaR G Steis, J A Carrasquillo, R McCabe, et al.
Blood|November 1, 1988
Rearrangement of both immunoglobulin and T-cell receptor genes in a prolymphocytic variant of hairy cell leukemia patient resistant to interferon-alphaS L Giardina, H A Young, C R Faltynek, et al.
British Journal of Cancer|June 30, 2005
A phase I clinical trial of continual alternating etoposide and topotecan in refractory solid tumoursR T Penson, M V Seiden, U A Matulonis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1990
Treatment of hairy cell leukemia with alternating cycles of pentostatin and recombinant leukocyte A interferon: results of a phase II studyA Martin, S Nerenstone, W J Urba, et al.
Pageof 22